HYPR
NEUTRAL
$1.21
Live
Hyperfine, Inc. · NASDAQ
Target $2.05
(+69.4%)
$0.53
52W Range
$2.22
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 12, 2026
Market cap
$119.21M
P/E
N/A
ROE
-79.0%
Profit margin
-262.3%
Debt/Equity
0.01
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
HYPR presents a high-risk, high-reward profile characterized by a stable Piotroski F-Score of 4/9 and a lack of traditional valuation benchmarks due to negative earnings. The company is experiencing explosive revenue growth (128% YoY) and maintains a strong liquidity position with a Current Ratio of 4.34 and negligible debt. However, these strengths are offset by severe profit margins (-262.29%) and a bearish insider sentiment. The stock is currently a speculative growth play where the market is pricing in future scalability rather than current fundamentals.
Key Strengths
Explosive revenue growth of 128% YoY
Strong liquidity with a Current Ratio of 4.34
Very low leverage (Debt/Equity of 0.01)
Healthy Gross Margin of 49.79% indicating product value
Significant upside to analyst target price of $2.05
Key Risks
Severe negative profit margins (-262.29%)
Bearish insider activity with consistent selling by C-suite executives
High valuation relative to sales (P/S of 8.79) for a non-profitable firm
Poor earnings track record with only 1 of the last 4 quarters beating estimates
High volatility and significant 5-year price depreciation (-88.1%)
AI Fair Value Estimate
Based on comprehensive analysis
$1.63
+34.7% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
39
Weak
30
85
20
60
0
AI Verdict
Speculative Growth
Key drivers: Hyper-growth in revenue, Strong balance sheet liquidity, Extreme operational burn rate, Negative insider sentiment
Confidence
80%
Value
30/100
Ref P/E N/A, P/S 8.79
Positives
- Price/Book is moderate at 2.87
Watchpoints
- P/S ratio of 8.79 is expensive for the sector
- No Graham Number due to lack of earnings
Future
85/100
Ref Growth rates
Positives
- 128% YoY Revenue growth
- Improving EPS growth (+42.9%)
Watchpoints
- Consistent failure to meet earnings estimates
Past
20/100
Ref Historical trends
Positives
- Recent 1Y recovery (+81.4%)
Watchpoints
- Devastating 5Y return of -88.1%
Health
60/100
Ref Piotroski F-Score 4/9
Positives
- Low Debt/Equity (0.01)
- High Quick Ratio (3.56)
Watchpoints
- Piotroski F-Score is only 4/9 (Stable but not strong)
Dividend
0/100
Ref Yield N/A
Positives
No standout positives identified.
Watchpoints
- No dividend policy
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$1.21
Analyst Target
$2.05
Upside/Downside
+69.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for HYPR and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
HYPR
Hyperfine, Inc.
Primary
|
-88.1% | -17.1% | +81.4% | -30.9% | +2.5% | +7.1% |
|
FONR
FONAR Corporation
Peer
|
+3.3% | +15.4% | +48.2% | +20.1% | +0.7% | +0.1% |
|
DH
Definitive Healthcare Corp.
Peer
|
-97.5% | -89.8% | -57.4% | -66.5% | -13.7% | -13.0% |
|
IPHA
Innate Pharma S.A.
Peer
|
-67.1% | -58.3% | -22.5% | -30.5% | -9.0% | +2.9% |
|
IMDX
Insight Molecular Diagnostics Inc.
Peer
|
-97.0% | -53.0% | +9.3% | -18.5% | -39.6% | -15.7% |
HYP
Hyperfine, Inc.
Primary
5Y
-88.1%
3Y
-17.1%
1Y
+81.4%
6M
-30.9%
1M
+2.5%
1W
+7.1%
FON
FONAR Corporation
Peer
5Y
+3.3%
3Y
+15.4%
1Y
+48.2%
6M
+20.1%
1M
+0.7%
1W
+0.1%
DH
Definitive Healthcare Corp.
Peer
5Y
-97.5%
3Y
-89.8%
1Y
-57.4%
6M
-66.5%
1M
-13.7%
1W
-13.0%
IPH
Innate Pharma S.A.
Peer
5Y
-67.1%
3Y
-58.3%
1Y
-22.5%
6M
-30.5%
1M
-9.0%
1W
+2.9%
IMD
Insight Molecular Diagnostics Inc.
Peer
5Y
-97.0%
3Y
-53.0%
1Y
+9.3%
6M
-18.5%
1M
-39.6%
1W
-15.7%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-3.67
PEG Ratio
N/A
P/B Ratio
2.87
P/S Ratio
8.79
EV/Revenue
6.17
EV/EBITDA
-2.33
Market Cap
$119.21M
Profitability
Profit margins and return metrics
Profit Margin
-262.29%
Operating Margin
-144.87%
Gross Margin
49.79%
ROE
-79.01%
ROA
-40.61%
Growth
Revenue and earnings growth rates
Revenue Growth
+128.0%
Earnings Growth
N/A
Q/Q Revenue Growth
+128.05%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.01
Low debt
Current Ratio
4.34
Strong
Quick Ratio
3.56
Excellent
Cash/Share
$0.36
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
50.9%
Op. Margin
-144.9%
Net Margin
-111.7%
Total Assets
$0.1B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
0.35x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
101%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-13
$N/A
2026-03-18
$-0.08
+2.1% surprise
2025-11-13
$-0.14
-33.3% surprise
2025-08-13
$-0.12
Healthcare Sector Comparison
Comparing HYPR against 264 companies in the Healthcare sector
(20 bullish, 87 neutral, 157 bearish)
Return on Equity (ROE)
-79.01%
This Stock
vs
-46.09%
Sector Avg
+71.4%
(Excellent)
Profit Margin
-262.29%
This Stock
vs
-19.58%
Sector Avg
+1239.3%
(Superior)
Debt to Equity
0.01
This Stock
vs
4.1
Sector Avg
-99.8%
(Less Debt)
Revenue Growth
128.0%
This Stock
vs
88.16%
Sector Avg
+45.2%
(Fast Growth)
Current Ratio
4.34
This Stock
vs
3.58
Sector Avg
+21.3%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
HYPR
Hyperfine, Inc.
|
NEUTRAL | $119.21M | - | -79.0% | -262.3% | $1.21 | |
|
FONR
FONAR Corporation
|
NEUTRAL | $117.26M | 16.18 | 6.0% | 7.1% | $18.61 | Compare |
|
DH
Definitive Healthcare Corp.
|
NEUTRAL | $111.79M | - | -40.4% | -57.5% | $1.07 | Compare |
|
IPHA
Innate Pharma S.A.
|
BEARISH | $132.24M | - | -% | -% | $1.41 | Compare |
|
IMDX
Insight Molecular Diagnostics Inc.
|
BEARISH | $101.97M | - | -% | -% | $3.17 | Compare |
HYPR
Hyperfine, Inc.
NEUTRAL
Mkt Cap
$119M
P/E
-
ROE
-79.0%
Price
$1.21
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-31 | SAINZ MARIA DEGOIS | Chief Executive Officer | Stock Award | 750,000 | - |
| 2026-03-31 | HALE BRETT | Chief Financial Officer | Stock Award | 330,000 | - |
| 2026-03-31 | TEISSEYRE THOMAS | Chief Operating Officer | Stock Award | 330,000 | - |
| 2026-03-23 | HALE BRETT | Chief Financial Officer | Sale | 24,188 | $29,267 |
| 2026-03-23 | TEISSEYRE THOMAS | Chief Operating Officer | Sale | 24,188 | $29,267 |
| 2026-02-13 | TEISSEYRE THOMAS | Chief Operating Officer | Sale | 821 | $913 |
| 2025-11-19 | TEISSEYRE THOMAS | Chief Operating Officer | Sale | 1,405 | $1,517 |
SAINZ MARIA DEGOIS
Chief Executive Officer
2026-03-31
750,000 shares
HALE BRETT
Chief Financial Officer
2026-03-31
330,000 shares
TEISSEYRE THOMAS
Chief Operating Officer
2026-03-31
330,000 shares
HALE BRETT
Chief Financial Officer
2026-03-23
24,188 shares
·
$29,267
TEISSEYRE THOMAS
Chief Operating Officer
2026-03-23
24,188 shares
·
$29,267
TEISSEYRE THOMAS
Chief Operating Officer
2026-02-13
821 shares
·
$913
TEISSEYRE THOMAS
Chief Operating Officer
2025-11-19
1,405 shares
·
$1,517
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
2 analysts
Lake Street
2026-03-19
Buy
Buy
Past News Coverage
Recent headlines mentioning HYPR from our newsroom.
Newest → oldest
No matching news yet.